Business Context and Reporting Period
This Form 8-K Current Report was filed by PMV Pharmaceuticals, Inc. on January 5, 2022, regarding corporate governance changes effective on that date. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol PMVP.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation of Director: Peter Thompson, M.D., resigned as a member of the Board of Directors, as well as the Compensation Committee and Nominating and Corporate Governance Committee, effective January 5, 2022. The resignation was not related to any disagreement with the Company regarding operations, policies, or practices.
- Election of Director: Kirsten Flowers was unanimously appointed as a director and Class I director to fill the vacancy created by Dr. Thompson's resignation. Her appointment was effective January 5, 2022.
Guidance, Outlook, and Management Commentary
Ms. Flowers' term as a Class I director will expire at the Company's annual meeting of stockholders in 2024 or upon the election of a successor. Her compensation will align with the Company's Outside Director Compensation Policy. An indemnification agreement was executed with Ms. Flowers in a form substantially similar to those held by other directors. The filing notes no family relationships between Ms. Flowers and other directors or officers, and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the background and qualifications of the newly appointed director, Kirsten Flowers.
- Review the Company's Outside Director Compensation Policy (referenced in the 2020 Form 10-K) to understand the financial implications of the new appointment.
- Confirm the composition of the Board's Compensation and Nominating and Corporate Governance Committees following Dr. Thompson's departure.
- Check for any subsequent filings regarding the appointment of a replacement for Dr. Thompson's committee roles if not immediately filled.